InnovoTEX
Austin, US · Founded 2022 · Delaware corporation
Innovotex develops macrocycle-mediated targeted delivery systems for cancer therapies, building multi-modal platforms intended to improve the effectiveness of targeted cancer treatments. The company operates in oncology-focused therapeutics.
Founders & leadership
InnovoTEX was founded in 2022 by Jonathan Arambula.
JA
Jonathan ArambulainFounder
JS
Jonathan SesslerNamed on SEC filing
KK
Krystle KarosikNamed on SEC filing
JA
Joseph ArambulaNamed on SEC filing
KK
Krystle KaroscikNamed on SEC filing
JH
James HusseyNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$3.6M disclosed across 3 rounds · 2023–2026
▶$2.7MraisedAug 2026 · 21 investors · BiotechnologyRule 506(b)
▶$2.7MraisedAug 2026 · 21 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Krystle KaroscikExecutive Officer, Director
- Jonathan ArambulaDirector
- Jonathan SesslerDirector
- James HusseyDirector
- Offering amount
- $4M
- Amount sold
- $2.7M
- First sale
- Nov 2024
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
▶$75KraisedAug 2026 · 2 investors · BiotechnologyRule 506(b)
▶$75KraisedAug 2026 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Krystle KaroscikExecutive Officer, Director
- Jonathan ArambulaDirector
- Jonathan SesslerDirector
- James HusseyDirector
- Offering amount
- $75K
- Amount sold
- $75K
- First sale
- Mar 2026
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
▶$829.8KraisedMar 2023 · 8 investors · Other Health CareRule 506(b)
▶$829.8KraisedMar 2023 · 8 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Jonathan SesslerDirector
- Krystle KarosikExecutive Officer
- Joseph ArambulaExecutive Officer, Director
- Offering amount
- $829.8K
- Amount sold
- $829.8K
- First sale
- Mar 2023
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlapNuvectis6 shared keywordsNuvectis is a biopharmaceutical company developing oral small molecule therapies for cancer, including NXP900, an SRC Family Kinase inhibitor, and NXP800, a GCN2 activator being evaluated in solid tumors such as ovarian cancer and cholangiocarcinoma. Its drug candidates are in early-stage clinical trials for patients with advanced solid tumors.
Renovo Rx5 shared keywordsRenovoRx develops targeted oncology therapies and commercializes the RenovoCath, an FDA-cleared drug-delivery device for intra-arterial chemotherapy administration in cancer treatment. The company is conducting Phase III clinical trials of its proprietary TAMP therapy platform for treating locally advanced pancreatic cancer with improved safety and efficacy compared to systemic chemotherapy.
Exelixis4 shared keywordsExelixis is an oncology company that discovers and develops cancer treatments, including small molecule therapeutics and biotherapeutics such as antibody-drug conjugates, for patients across multiple tumor types. Its flagship commercial product is CABOMETYX (cabozantinib), and it operates through global development and commercialization partnerships.
Companies competing with InnovoTEX for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does InnovoTEX do?
- Innovotex develops macrocycle-mediated targeted delivery systems for cancer therapies, building multi-modal platforms intended to improve the effectiveness of targeted cancer treatments. The company operates in oncology-focused therapeutics.
- Who founded InnovoTEX?
- InnovoTEX was founded by Jonathan Arambula in 2022.
- How much funding has InnovoTEX raised?
- InnovoTEX has disclosed $3.6M raised across 3 rounds.
- Where is InnovoTEX headquartered?
- InnovoTEX is headquartered in Austin, US.